AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34503985 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5 µg/25 µg
Number of subjects: 73
Study 34503985 — intervention group
Group type: COMPARATOR
Intervention: Navafenterol and UMEC/VI
Number of subjects: 73
Study 32977348 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy (placebo-controlled trial)
Number of subjects: 0
Study 32977348 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine airway clearance and treatment of recurrent respiratory tract infections
Number of subjects: 0
Study 32977348 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-specific treatment for non-respiratory symptoms
Number of subjects: 0
Study 32977348 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in patient registries
Number of subjects: 0
Study 32977348 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of genotype-specific course of the disease
Number of subjects: 0
Study 32127889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative low-dose ketamine (0.15mg/kg bolus at induction and continuous infusion of 0.12 mg/kg/hour till start of skin closure)
Number of subjects: 46
Study 32127889 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 46
Study 32127889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received Morphine 0.1 mg/kg IV at debulking
Number of subjects: 46
Study 35995357 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined external ventricular drainage and endoscope‐assisted microsurgery
Number of subjects: 41
Study 35995357 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study 33315503 — intervention group
Group type: COMPARATOR
Intervention: Fat graft injections
Number of subjects: 45
Study 33315503 — intervention group
Group type: COMPARATOR
Intervention: Nanofat-enriched fat graft injections
Number of subjects: 45
Study 32447857 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus hyperbaric oxygen (HBO) therapy
Number of subjects: 28
Study 32447857 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple HBO therapy)
Number of subjects: 28
Study 35993176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1158
Study 35993176 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1158
Study 34473822 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional bundle (A: sporicidal cleaning, B: probiotics, C: improvement in personal hygiene)
Number of subjects: 25311
Study 34473822 — intervention group
Group type: COMPARATOR
Intervention: Individual interventions (A, B, C)
Number of subjects: 25311
Study 36056784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional purified protein derivative (PPD) injected at a dose of 0.1 ml every 2 weeks until complete improvement or for a maximum of four sessions.
Number of subjects: 80
Study 36056784 — intervention group
Group type: COMPARATOR
Intervention: Intralesional Candida antigen (CA) injected at a dose of 0.1 ml every 2 weeks until complete improvement or for a maximum of four sessions.
Number of subjects: 80
Study 33492782 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP education (experimental group)
Number of subjects: 80
Study 33492782 — intervention group
Group type: COMPARATOR
Intervention: Self-directed EBP education (control group)
Number of subjects: 80
Study 35364051 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine sternal block
Number of subjects: 52
Study 35364051 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 52
Study 36155998 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ozone therapy
Number of subjects: 153
Study 36155998 — intervention group
Group type: COMPARATOR
Intervention: Injection of anti‐inflammatory analgesic solution into the internal orifice of nerve root
Number of subjects: 153
Study 36155998 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine hook operation (in addition to basic group treatment)
Number of subjects: 153
Study 34036813 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus auricular acupressure treatment twice weekly for 6 weeks
Number of subjects: 30
Study 34036813 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus auricular acupressure treatment
Number of subjects: 30
Study 33175623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocolloidal silver-based gel (SilvoGel)
Number of subjects: 32
Study 33175623 — intervention group
Group type: COMPARATOR
Intervention: Eosin 2% solution
Number of subjects: 32
Study 35262716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary prehabilitation (4 supervised sessions, 2 sessions per week for at least 2 months before TKR)
Number of subjects: 262
Study 35262716 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information booklet and standard advice by the orthopedic surgeon)
Number of subjects: 262
Study 35262716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary prehabilitation
Number of subjects: 262
Study 35262716 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 262
Study 32508281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 0
Study 32788154 — intervention group
Group type: EXPERIMENTAL
Intervention: ConnEDCt mobile EDC framework for iOS devices and personal computers
Number of subjects: 0
Study 35587267 — intervention group
Group type: EXPERIMENTAL
Intervention: Two mimotopes synthesized as mimotopes of dopamine
Number of subjects: 0
Study 35587267 — intervention group
Group type: COMPARATOR
Intervention: Selegiline (commercial inhibitor of MAO-B)
Number of subjects: 0
Study 34247040 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine group (27 g of alcohol per day)
Number of subjects: 0
Study 34247040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol group (27 g of alcohol per day)
Number of subjects: 0
Study 34247040 — intervention group
Group type: COMPARATOR
Intervention: No alcohol group
Number of subjects: 0
Study 35051648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP-gluten-free diet
Number of subjects: 70
Study 35051648 — intervention group
Group type: COMPARATOR
Intervention: Usual gluten-free diet
Number of subjects: 70
Study 34516591 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive verbalization (PV)
Number of subjects: 73
Study 34516591 — intervention group
Group type: COMPARATOR
Intervention: Negative verbalization (NV)
Number of subjects: 73
Study 34997314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous placebo + oral cetirizine 10 mg
Number of subjects: 37
Study 34997314 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diphenhydramine 50 mg + oral placebo
Number of subjects: 37
Study 34997314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 34318757 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose CT (120 kV and 300 mA)
Number of subjects: 740
Study 34318757 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CT (80 kV and 40 mA)
Number of subjects: 740
Study 34318757 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose CT
Number of subjects: 740
Study 34318757 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CT
Number of subjects: 740
Study 32170307 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I followed by PAP
Number of subjects: 121
Study 32170307 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I concurrent with PAP
Number of subjects: 121
Study 32170307 — intervention group
Group type: COMPARATOR
Intervention: PAP only
Number of subjects: 121
Study 35642330 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals
Number of subjects: 60632
Study 35642330 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 60632
Study 35642330 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated seropositive individuals
Number of subjects: 60632
Study 34530316 — intervention group
Group type: EXPERIMENTAL
Intervention: VOICES (n = 51)
Number of subjects: 113
Study 34530316 — intervention group
Group type: COMPARATOR
Intervention: GirlHealth (attention control; n = 62)
Number of subjects: 113
Study 34530316 — intervention group
Group type: COMPARATOR
Intervention: Both conditions
Number of subjects: 113
Study 35240285 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-Posterior Axis Line (APAL)
Number of subjects: 32
Study 35240285 — intervention group
Group type: COMPARATOR
Intervention: Transepicondylar Axis Line (TEAL)
Number of subjects: 32
Study 35240285 — intervention group
Group type: EXPERIMENTAL
Intervention: APAL
Number of subjects: 32
Study 35240285 — intervention group
Group type: COMPARATOR
Intervention: TEAL
Number of subjects: 32
Study 35240285 — intervention group
Group type: EXPERIMENTAL
Intervention: APAL and TEAL
Number of subjects: 32
Study 32283195 — intervention group
Group type: COMPARATOR
Intervention: Oleogel-dissolved CoQ10 (1 g CoQ10/5 g oleogel-disk)
Number of subjects: 0
Study 32283195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel-dissolved CoQ10 (repeated-dose for 14 days)
Number of subjects: 0
Study 32283195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel-dissolved CoQ10
Number of subjects: 0
Study 32283195 — intervention group
Group type: COMPARATOR
Intervention: Control (solid form of CoQ10)
Number of subjects: 0
Study 36346322 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrum Red (2.5 mg THC, 0.3 mg CBD/softgel)
Number of subjects: 83
Study 36346322 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectrum Yellow (0.9 mg THC, 20 mg CBD/mL of oil)
Number of subjects: 83
Study 36346322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 33572499 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training) - 6 weeks, 12 bouts first 2 weeks, 16 bouts in weeks 3 and 4, and 20 bouts in the last two weeks x 30‐s intervals interspersed with 1‐min rest periods, performed thrice weekly
Number of subjects: 19
Study 33572499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 19
Study 32318695 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg once daily for 20 weeks
Number of subjects: 124
Study 32318695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 36084047 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month multi-component health promotion programme based on educational and motivational strategies
Number of subjects: 288
Study 36084047 — intervention group
Group type: COMPARATOR
Intervention: Basic educational strategy (control group)
Number of subjects: 288
Study 36084047 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month multi-component health promotion programme
Number of subjects: 288
Study 33248975 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg intravenous tranexamic acid
Number of subjects: 30
Study 33248975 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg intravenous tranexamic acid
Number of subjects: 30
Study 33248975 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous tranexamic acid
Number of subjects: 30
Study 35414602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose treatment (serum glucose <110 mg/dL)
Number of subjects: 146
Study 35414602 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (serum glucose <180 mg/dL)
Number of subjects: 146
Study 32599647 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide local excision (WLE)
Number of subjects: 547
Study 32599647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 547
Study 32599647 — intervention group
Group type: COMPARATOR
Intervention: WLE
Number of subjects: 547
Study 32599647 — intervention group
Group type: COMPARATOR
Intervention: MMS
Number of subjects: 547
Study 32599647 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical management
Number of subjects: 547
Study 32429680 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 2
Study 32429680 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (diclofenac sodium)
Number of subjects: 2
Study 32429680 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and pharmacological treatment (diclofenac sodium)
Number of subjects: 2
Study 34358953 — intervention group
Group type: EXPERIMENTAL
Intervention: High g1 treatment
Number of subjects: 40
Study 34358953 — intervention group
Group type: COMPARATOR
Intervention: Standard g1 treatment
Number of subjects: 40
Study 32181830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaerosol spray sunscreen
Number of subjects: 0
Study 32181830 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 35766288 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention with four home visits over 1 year
Number of subjects: 420
Study 35766288 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 420
Study 33590999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintubation noninvasive ventilation
Number of subjects: 2427
Study 33067280 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of mental healthcare (psychometric testing by GP, talk therapy by GP, contact with a psychologist, contact with a psychiatrist, psychotropic medication)
Number of subjects: 350
Study 33067280 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 350
Study 33067280 — intervention group
Group type: EXPERIMENTAL
Intervention: Less impaired mental health
Number of subjects: 350
Study 33067280 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic factors
Number of subjects: 350
Study 35678328 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-based maintenance regimens after FOLFOX/panitumumab induction
Number of subjects: 229
Study 34206058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B birth dose vaccine (HepB‐BD) administered to infants in addition to routine vaccines (0-8-12-16 weeks) during the intervention period.
Number of subjects: 24
Study 34206058 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunization schedule (8-12-16 weeks) during the control period.
Number of subjects: 24
Study 36377268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecha Kucha method training via smartphones
Number of subjects: 70
Study 36377268 — intervention group
Group type: COMPARATOR
Intervention: Classical verbal instruction method
Number of subjects: 70
Study 34142748 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive-behavior therapy (tCBT)
Number of subjects: 191
Study 34142748 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 191
Study 32392091 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Reported Stuttering Severity (SRSS)
Number of subjects: 0
Study 32392091 — intervention group
Group type: COMPARATOR
Intervention: Percentage Syllables Stuttered (%SS)
Number of subjects: 0
Study 34799999 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐mediated intervention (adapted responsive teaching; ART)
Number of subjects: 0
Study 34799999 — intervention group
Group type: COMPARATOR
Intervention: Referral to early intervention and monitoring (REIM)
Number of subjects: 0
Study 33657282 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic markers and lifestyle factors for longevity classification
Number of subjects: 15651
Study 33657282 — intervention group
Group type: COMPARATOR
Intervention: Genetic association with longevity loci
Number of subjects: 15651
Study 33657282 — intervention group
Group type: COMPARATOR
Intervention: Polygenic risk scores and Mendelian randomization analyses
Number of subjects: 15651
Study 35944602 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain management program (3-week duration)
Number of subjects: 103
Study 34276288 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cyborg Hybrid Assistive Limb (HAL)
Number of subjects: 40
Study 34276288 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (CGT)
Number of subjects: 40
Study 32897297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline at burn-in
Number of subjects: 402
Study 32897297 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 402
Study 35981838 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard (PLC Medical Systems)
Number of subjects: 259
Study 35981838 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline hydration (control)
Number of subjects: 259
Study 33030846 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (performed twice a week for ten sessions)
Number of subjects: 12
Study 35546299 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with 915 nm diode laser (1.5 W, duty cycle of 60%, energy density of 72 J cm²)
Number of subjects: 32
Study 33437904 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm using soluble immune markers (SIMs)
Number of subjects: 43
Study 33437904 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm using a combination of IL-2, MIG/CCL9, RANTES/CCL5, SCF, and TRAIL
Number of subjects: 43
Study 33437904 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B core antigen
Number of subjects: 43
Study 33437904 — intervention group
Group type: EXPERIMENTAL
Intervention: Single SIMs at the time of NA stop
Number of subjects: 43
Study 33549155 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D navigation for sacroiliac screw fixation
Number of subjects: 0
Study 33549155 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure for sacroiliac screw fixation
Number of subjects: 0
Study 33549155 — intervention group
Group type: COMPARATOR
Intervention: 2D navigation for sacroiliac screw fixation
Number of subjects: 0
Study 33549155 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation-assisted pedicle screw stabilization
Number of subjects: 0
Study 33549155 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint replacements (various procedures)
Number of subjects: 0
Study 34090838 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE strategies implemented at 3 WIC clinics
Number of subjects: 246
Study 34090838 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 246
Study 32985237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 0
Study 32985237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nutritional supplementation and resistance exercise
Number of subjects: 0
Study 34142184 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of autologous micro-fragmented adipose tissue
Number of subjects: 31
Study 32319087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg rocuronium iv
Number of subjects: 40
Study 32319087 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg rocuronium iv
Number of subjects: 40
Study 32319087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional drug administration)
Number of subjects: 40
Study 32319087 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 40
Study 32319087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium administration
Number of subjects: 40
Study 36184206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 360
Study 36184206 — intervention group
Group type: EXPERIMENTAL
Intervention: Week on Week off (WOWO)
Number of subjects: 360
Study 36184206 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐Hour Time‐Restricted Eating (TRE‐6)
Number of subjects: 360
Study 36184206 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐Hour Time‐Restricted Eating (TRE‐8)
Number of subjects: 360
Study 36184206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative Day Diet (ADD)
Number of subjects: 360
Study 33914302 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lymphadenectomy (SLND) in 169 patients (70.1%)
Number of subjects: 241
Study 33914302 — intervention group
Group type: COMPARATOR
Intervention: Control group (72 patients (29.9%) who did not undergo SLND)
Number of subjects: 241
Study 35719707 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg twice a day)
Number of subjects: 84
Study 35719707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 mg twice a day)
Number of subjects: 84
Study 35719707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg microcrystalline cellulose twice a day)
Number of subjects: 84
Study 32687612 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS-6637 (36 participants)
Number of subjects: 48
Study 32687612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 participants)
Number of subjects: 48
Study 32619032 — intervention group
Group type: EXPERIMENTAL
Intervention: P3-MumBubVax intervention
Number of subjects: 0
Study 32520623 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-5074 0.25 mg
Number of subjects: 240
Study 32520623 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-5074 0.5 mg
Number of subjects: 240
Study 32520623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 32520623 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-5074 (both doses)
Number of subjects: 240
Study 33653633 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable-Polymer Sirolimus-Eluting Stents (BP-SES)
Number of subjects: 1131
Study 33653633 — intervention group
Group type: COMPARATOR
Intervention: Durable-Polymer Everolimus-Eluting Stents (DP-EES)
Number of subjects: 1131
Study 34856759 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 65
Study 34856759 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) with Whole-Body Cryotherapy (WBC)
Number of subjects: 65
Study 35271932 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐cTnI testing
Number of subjects: 46927
Study 35320960 — intervention group
Group type: EXPERIMENTAL
Intervention: Median approach for subarachnoid block
Number of subjects: 100
Study 35320960 — intervention group
Group type: COMPARATOR
Intervention: Paramedian approach for subarachnoid block
Number of subjects: 100